

27 June 2024 EMA/CHMP/352892/2023 rev.6

Timetable for the procedure

Referral under Article 20 of Regulation (EC) No 726/2004

Procedure no: EMEA/H/C/003687/A20/0065

Mysimba

Procedural step	Date
Notification:	01 September 2023
Start of the procedure (CHMP ¹):	September 2023 CHMP
List of questions ² :	30 May 2024
Submission of responses:	18 October 2024
Re-start of the procedure:	14 November 2024
Rapporteur/co-rapporteur assessment reports circulated to CHMP:	21 November 2024
Comments:	28 November 2024
Updated rapporteur/co-rapporteur assessment reports circulated to CHMP:	04 December 2024
CHMP list of outstanding issues or CHMP opinion:	December 2024 CHMP

² At the May 2024 CHMP meeting, a new Rapporteur was appointed and the procedure was reset to day 1



An agency of the European Union

© European Medicines Agency, 2024. Reproduction is authorised provided the source is acknowledged.

¹ Committee for Medicinal Products for Human Use

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000